A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

PHASE2CompletedINTERVENTIONAL
Enrollment

338

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

May 16, 2022

Study Completion Date

November 22, 2022

Conditions
ObesityOverweight
Interventions
DRUG

LY3437943

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (28)

15212

Allegheny Endocrinology Associates, Pittsburgh

32216

East Coast Institute for Research, LLC, Jacksonville

33331

Encore Medical Research - Weston, Weston

34652

Suncoast Clinical Research, Inc., New Port Richey

37909

New Phase Research and Development, Knoxville

62711

Springfield Diabetes & Endocrine Center, Springfield

63303

StudyMetrix Research, City of Saint Peters

66606

Cotton O'Neil Diabetes and Endocrinology Center, Topeka

70072

Tandem Clinical Research,LLC, Marrero

73069

Intend Research, LLC, Norman

75149

Southern Endocrinology Associates, Mesquite

75230

Dallas Diabetes Research Center, Dallas

77054

Juno Research, Houston

77079

Endocrine Ips, Pllc, Houston

78731

Texas Diabetes & Endocrinology, P.A., Austin

85254

Perseverance Research Center, Scottsdale

90057

Velocity Clinical Research, Huntington Park, Los Angeles

90255

Velocity Clinical Research, Huntington Park, Huntington Park

92701

Southern California Dermatology, Inc., Santa Ana

92801

Anaheim Clinical Trials, LLC, Anaheim

93003

Coastal Metabolic Research Centre, Ventura

93720

Valley Research, Fresno

94598

Diablo Clinical Research, Inc., Walnut Creek

98057

Rainier Clinical Research Center, Renton

08869

Amici Clinical Research LLC, Raritan

00970

Private Practice - Dr. Paola Mansilla-Letelier, Guaynabo

00917

GCM Medical Group, PSC - Hato Rey Site, San Juan

00935

San Juan City Hospital, San Juan

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY